SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The total revenue stands at Rs. 679.80 millions for the September 2024 quarter. The mentioned figure indicates an increase of about 101.64% as against Rs. 337.13 millions during  the year-ago period.The Net Loss for the quarter ended September 2024 is Rs. -400.22 millions as compared to Net Loss of Rs. -866.61 millions of corresponding quarter ended September 2023 Operating profit Margin for the quarter ended September 2024 improved to 7.07% as compared to -381.03% of corresponding quarter ended September 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202409 202309 % Var
Sales 679.80 337.13 101.64 679.80 337.13 101.64 679.80 337.13 101.64
Other Income 5.84 0.89 556.18 5.84 0.89 556.18 5.84 0.89 556.18
PBIDT 7.07 -381.03 -101.86 7.07 -381.03 -101.86 7.07 -381.03 -101.86
Interest 207.14 245.47 -15.61 207.14 245.47 -15.61 207.14 245.47 -15.61
PBDT -209.61 -682.29 -69.28 -209.61 -682.29 -69.28 -209.61 -682.29 -69.28
Depreciation 190.61 184.32 3.41 190.61 184.32 3.41 190.61 184.32 3.41
PBT -400.22 -866.61 -53.82 -400.22 -866.61 -53.82 -400.22 -866.61 -53.82
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -400.22 -866.61 -53.82 -400.22 -866.61 -53.82 -400.22 -866.61 -53.82
Equity 41.55 40.10 3.62 41.55 40.10 3.62 41.55 40.10 3.62
PBIDTM(%) 1.04 -113.02 -100.92 1.04 -113.02 -100.92 1.04 -113.02 -100.92

Onesource Specialty Share Price

1550.60 -12.20 (-0.78%)
25-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.15
Dr. Reddys Labs. 1350.00
Cipla 1440.30
Zydus Lifesciences 1101.50
Lupin 2342.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: